The effects of insulin infusion on cardiac autonomic nervous system (ANS) activity were investigated in healthy subjects (n l 15) and in patients with various types of insulin-resistance, such as obese subjects (n l 20) and those with hypertension (n l 15) or type II (non-insulindependent) diabetes (n l 22). Healthy subjects and patients underwent euglycaemic hyperinsulinaemic glucose clamp, and cardiac ANS and haemodynamic changes were investigated by continuous recording of heart rate variability by the Holter technique and by venous occlusion plethysmography respectively. At baseline, healthy subjects had the highest values for total spectral power and the low-frequency (LF) component, and the lowest value for the highfrequency (HF) component. In the pooled data (n l 72), the fasting plasma insulin concentration was correlated with baseline total spectral power (r l k0.37 ; P 0.001) and the LF/HF ratio (r l k0.35 ; P 0.003). Such correlations were still significant (P 0.01 for both) after adjustment for body fat and mean arterial blood pressure. In a multivariate linear stepwise analysis (n l 72), a model including body fat, waist/hip ratio, fasting plasma glucose concentration and insulin-mediated glucose uptake explained 47 % of the variability of the change in the LF/HF ratio, with body fat (t l k3.11 ; P 0.01) and insulin-mediated glucose uptake (t l k3.48 ; P 0.008) being significantly and independently associated with insulin-mediated changes in the LF/HF ratio. Insulin infusion reduced the total spectral power and increased the LF/HF ratio in healthy subjects, but not in insulin-resistant patients. In conclusion, our study demonstrates that insulin fails to stimulate cardiac ANS activity in insulin-resistant patients, independently of the causes of insulin resistance.
INTRODUCTION
Power spectral analysis of heart rate variability (HRV) is a useful and safe tool for the evaluation of cardiac autonomic nervous system (ANS) activity [1, 2] . More recently, glucose ingestion has been shown to increase the ratio between the low-frequency (LF) and highfrequency (HF) components of spectral power (LF\HF ratio) in healthy subjects with different body fat contents [3] . However, that study tested the effects of glucose ingestion on HRV without differentiating the potential effects of glucose itself from those of insulin [3] . Since insulin stimulates sympathetic nervous system activity [4, 5] , a relationship between insulin action and cardiac ANS activity cannot be ruled out. Indeed, it has been shown that insulin infusion stimulates cardiac ANS activity in healthy subjects [6, 7] , but not in obese patients [6] . Whether the lack of an effect of insulin on cardiac ANS activity is confined to obese patients or is a characteristic of the insulin-resistant state still needs to be investigated. Thus our study aims to investigate the effects of insulin infusion on cardiac ANS activity in healthy subjects and in patients affected by different insulin-resistant conditions, such as obesity, hypertension and type II (non-insulin-dependent) diabetes mellitus. All subjects and patients underwent euglycaemic hyperinsulinaemic glucose clamp while cardiac ANS and haemodynamic changes were investigated by continuous recording of HRV by the Holter technique and by venous occlusion plethysmography respectively.
METHODS

Subjects
A total of 72 subjects volunteered for our study. Clinical characteristics of the study groups are shown in Table 1 . All subjects were studied after an overnight 14 h fast, and were required to refrain from drinking alcohol for 15 days before the study. None of the subjects were smokers. Each subject was admitted to our department 3 days before each study and was fed on an isocaloric diet with a caloric distribution of 50 % (w\w) carbohydrate, 30 % (w\w) fat and 20 % (w\w) protein. Sodium intake ranged from 4.5 to 6 g\day, depending on the weightmaintenance calorie requirement. All women were studied in the follicular phase. Hypertensive patients had been recently diagnosed, and were still untreated at the time of the study. Diabetic patients had good metabolic Table 1 Clinical characteristics of the study groups Abbreviations : BMI, body mass index ; SBP, systolic blood pressure ; DBP, diastolic blood pressure. The plasma noradrenaline concentration was determined after an overnight fast, and with the subject in a supine position. All results are meanspS.D. Statistically significant differences among the different groups are indicated by : *P 0.01 compared with healthy subjects ; †P 0.01 compared with hypertensive patients ; ‡P 0.01 compared with patients with type II diabetes. [8] . All subjects had been weight-stable for at least 3 months before the study, and none were participating in any regular exercise programme. All volunteers except for those with diabetes had normal glucose tolerance to a 75 g oral glucose load [9] . All subjects gave informed consent to participate in the study, which was approved by the Ethical Committee of our Institution.
Anthropometric determinations
Weight and height were measured using standard techniques. Body mass index was calculated as body weight (kg)\[height (m)#]. Body fat and fat-free mass were measured using a four-terminal bioimpedance analyser (RJL Spectrum Bioelectrical Impedance IA 101\SC Akern ; RJL System, Florence, Italy). Waist circumference was measured at the mid-point between the lower rib margin and the iliac crest (normally umbilical level), and hip circumference was measured at the level of the trochanter. Both circumferences were measured to the nearest 0.5 cm with a plastic tape, and the waist\hip ratio was calculated.
Experimental design
The study protocol was designed to assess changes in HRV during insulin infusion. A control study with saline infusion was also performed. Each volunteer was studied on two separate occasions, 3 days apart. The order of the studies was assigned at random.
At 07.00 hours, a catheter was inserted into the right brachial vein for infusion of insulin and glucose. Another catheter was threaded into a wrist vein retrogradely, and the hand was placed in a heated box (" 60 mC) for sampling of arterialized blood. After basal measurements, subjects received square-wave infusion of regular insulin (Humulin R ; Eli Lilly, Florence, Italy) at a rate of 1 m-unit:kg −" :120 min −" (insulin study), with euglycaemia maintained via the clamp technique. In the control study, the saline load was matched to the overall volume of saline received during the insulin study without attempting to replace the free water load infused as 20 % (w\v) dextrose during the hyperinsulinaemic euglycaemic glucose clamp. Saline and insulin infusions were carried out for the same length of time. During each clamp. K # HPO % (0.0038 mmol:kg −" :min −" ) was infused to prevent hypokalaemia and hypophosphataemia. Serum potassium levels were 3.8 mmol\l at all times during the hyperinsulinaemic glucose clamp. Serum phosphate was unchanged from the basal value throughout the studies. Measurements of mean arterial blood pressure (MABP), leg (muscle) blood flow (LBF) and plasma noradrenaline (norepinephrine) concentrations were obtained at baseline and during the last 30 min (90-120 min) of the glucose clamp. Each LBF and plasma noradrenaline concentration value represents the mean of at least four determinations. HRV was determined in the 60 min preceding the start of the insulin infusion and throughout the clamp period.
Cardiovascular determinations
All cardiovascular measurements were carried out with subjects under quiet conditions, with the room temperature maintained at 21 mC. Before recording, all patients were asked to bed rest in a supine position for at least 30 min. Effort was made to keep patients unaware of the sampling timing, to avoid affecting the heart rate ; furthermore, all subjects were accustomed to breathe at a constant rate and advised to avoid talking during the study.
Before starting ambulatory ECG monitoring, baseline blood pressure was recorded using a standard mercury sphygmomanometer (diastolic blood pressure corresponding to Korotkoff's phase V). All determinations were carried out with the subject at rest after 15 min in the supine position ; measurements were made on three occasions separated by intervals of 5 min, and the mean value of the three measurements was then calculated and expressed as the baseline arterial blood pressure. During the clamp studies, arterial blood pressure and heart rate were determined in real time using a Finapres device (Omheda, Englewood, CO, U.S.A.). Respiratory frequency was also calculated over a period of 2 min before the test. We asked the subjects to breath to a normal frequency and thus we just counted the breaths. Subjects with a respiratory rate of less than 10 breaths\min (i.e. 0.15 Hz) were excluded from the study, in order to avoid the overlap of oscillations of LF and HF in spectral analysis.
Ambulatory ECG monitoring was performed using two-channel frequency modulator tape recorders (Remco Italy Cardioline AD 35 ; recorder model number LP103). In order to ensure that variations did not introduce frequency components into the data, after each experiment an expert technician checked the speed of the tape recorder. After accurate skin preparation, the electrodes were placed on the chest in order to place the bipolar chest leads CM1 (modified V1) on the first channel and CM4 (modified V4) on the second channel. Holter monitoring started 30 min after the superficial veins were cannulated. ECG was always recorded starting at 08.00 hours for a 180 min period (60 min baseline and 120 min along the glucose clamp). Two independent and blinded experienced investigators analysed the ambulatory ECG recording tapes using a Holter AD35 TOP instrument (Remco Italy Cardioline). Ectopic beats were corrected for linear interpolation with the adjacent complexes. ECG tracings with 1 % premature beats were eliminated from the analysis. Power spectral analysis was calculated from a consecutive series of 512 intervals.
An autoregressive algorithm computed the power spectral densities. According to this model, for any given signal at instant n, the signal amplitude x(n) is determined as the weighted linear sum of its ' p ' previous sample plus a random component, u(n):
where u(n), n l 1 … N form the samples of a stationary Gaussian white noise process, and K is a constant. The parameters a " ,a # … a p are to be determined, and are called autoregressive parameters. Autoregressive spectral analysis was undertaken after estimation of model coefficients using the Levinson-Durbin algorithm. The model order selection was performed according to the Akaike [10] information criterion. Spectral components were identified and estimated using the spectral-decomposition algorithm proposed by Johnsen and Andersen [11] and were then assigned, on the basis of their central frequency, to one of the three bands : the very-lowfrequency band (from 0 to 0.03 Hz), the LF band (from 0.03 to 0.15 Hz) or the HF band (from 0.15 to 0.45 Hz). Since the physiological explanation of the very-lowfrequency component is much less well defined and the existence of a specific physiological process attributable to these heart period changes has been strongly questioned [1] , only LF and HF components are normally considered. LF and HF components are reported in normalized units, which represent the relative value of each power component in proportion to the total power minus the very-low-frequency component [1] . Normalized units tend to minimize the effects of changes in total power on the values of the LF and HF components [1] . The respiratory rate, for data analysis, was obtained from the central frequency of the HF component as described by Pinciroli et al. [12] .
LBF was measured by using a mercury-in-silastic strain-gauge plethysmograph (EC 5R ; Hokanson, Milan, Italy) by a venous occlusion technique [13, 14] . LBF was calculated from the rate of increase in calf volume, while venous return from the calf was prevented by inflating the cuff on the upper leg. The pressure in the venous occlusion or congesting cuff was 40 mmHg. Circulation to the foot was arrested by a cuff inflated around the ankles during blood flow determinations, which were performed at 15 s intervals for 5 min during the baseline period and for the last 30 min of insulin infusion.
Analytical techniques
Plasma glucose was determined immediately by the glucose oxidase method (Beckman Autoanalyzer ; Beckman, Fullerton, CA, U.S.A.). Blood samples for insulin measurements were collected into heparinized tubes. After centrifugation, plasma insulin concentrations were determined by radioimmunoassay (Sorin Biomedical, Milan, Italy). Plasma noradrenaline concentrations were determined by HPLC.
Statistical analyses
All results are presented as meanspS.D. MABP was calculated as the diastolic blood pressure plus one-third of the pulse pressure. Because the distributions of both of the frequency domain measures of HRV and of plasma insulin concentrations were extremely skewed, each value was also log-transformed to improve normality for statistical testing and back-transformed for presentation in all Tables and Figures. Percentage changes in heart rate, LBF, LF\HF ratio and plasma noradrenaline concentrations were calculated, with basal values equal to 100 %. Analysis of variance (ANOVA) was used to establish the presence of differences among the groups. When a P value of 0.05 was found, a Scheffe! test was also performed. Correlations are Pearson product moment correlations. ANOVA for repeated measurements was performed to calculate time-dependent changes in the LF\HF ratio. Partial correlations allowed testing of the association between fasting hyperinsulinaemia and HRV parameters independent of body fat and MABP. Multivariate stepwise regression analysis was used to study the independent contributions of different covariates to insulin-induced changes in the LF\HF ratio. A P value of 0.05 was chosen as the level of significance. All calculations were carried out on an IBM PC computer using the SOLO software package (BMDP, Cork, Ireland).
RESULTS
All groups of subjects were similar in age, but patients with obesity and type II diabetes had values for body mass index, body fat and waist\hip ratio greater than those of control subjects and hypertensive patients ( Table  1) . The arterial blood pressure of hypertensive patients was significantly higher than in the other study groups (Table 1 ). In contrast, plasma noradrenaline concentrations, heart rate and baseline LBF were similar in all study groups. No differences were found between males and females.
Metabolic data
At baseline, the fasting plasma glucose concentration did not differ among study groups (Table 2 ). In contrast, fasting plasma insulin concentrations were significantly higher in insulin-resistant patients. In the last 60 min of the insulin infusion, the plasma glucose concentration was kept within a narrow range (coefficient of variation 5 % for all study groups) and close to basal values. Furthermore, steady-state plasma glucose and insulin concentrations were also similar in all study groups (Table 2) . Under these metabolic conditions, insulinmediated glucose uptake varied significantly among the study groups ; in particular, healthy subjects and patients with type II diabetes had the highest and the lowest insulin-mediated glucose uptake respectively. Insulin infusion evoked a significant rise in the plasma noradrenaline concentration (P 0.02 compared with baseline for all groups) and in LBF (P 0.03 compared with baseline for all groups). Nevertheless, the percentage increases in plasma noradrenaline concentration and in LBF averaged 19p4.3 % and 11p2.3 % respectively for the pooled data, without significant differences among the different study groups (P 0.12 for noradrenaline and P 0.18 or more for LBF for comparisons among all groups by ANOVA). Finally, basal MABP was unaffected by insulin infusion in both normotensive and hypertensive patients.
In the overall population study (n l 72), insulinmediated glucose uptake was correlated with fasting plasma insulin concentration (r l k0.61 ; P 0.001), body mass index (r l k0.53 ; P 0.001) and body fat (r l k0.69 ; P 0.001).
Effects of insulin on cardiac ANS activity (Table 3)
Differences among the groups A preliminary analysis was carried out to assess the potential role of respiration. The central HF component Insulin resistance and cardiac autonomic nervous system (reflecting the respiratory rate) was stable both before and during insulin infusion, with no differences among study groups. At baseline, the healthy subjects had the lowest values for total spectral power and the LF component, with the highest value for the HF component. In healthy subjects, insulin infusion was associated with a significant decrease in total spectral power, an increase in the normalized LF component and a decrease in the normalized HF component. Consequently, the LF\HF ratio was significantly higher during insulin infusion than at baseline. In obese patients and those with hypertension or type II diabetes, insulin infusion did not significantly affect total spectral power or the normalized LF or HF components ; thus, in insulin-resistant patients, the LF\HF ratio was slightly but not significantly increased by insulin infusion. Since healthy subjects had the lowest basal LF\HF ratio, we calculated the percentage changes in LF\HF ratio following insulin infusion. Healthy subjects had the strongest response to insulin infusion ; in contrast, no significant differences were found among the insulinresistant groups (Figure 1 ).
Differences between healthy subjects and the whole group of insulin-resistant patients
On comparing healthy subjects (n l 15) with the overall group of insulin-resistant patients (n l 57), insulin infusion had a significant inhibitory effect on total spectral power (P 0.05) in healthy subjects only, and not in the insulin-resistant patients (P 0.11). Similar results were found when the analysis was carried out for insulinmediated changes in the LF component (P 0.05 for healthy subjects ; P 0.22 for insulin-resistant patients), the HF component (P 0.05 for healthy subjects ; P 0.18 for insulin-resistant patients) and the LF\HF ratio (P 0.05 for healthy subjects ; P 0.12 for insulinresistant patients). Finally, on calculating the percentage changes in HRV parameters following insulin infusion, healthy subjects showed a greater decrease in total spectral power (21.9p7.3 % compared with 7.7p3.3%; P 0.007), increase in the LF component (9.8p1.1 % compared with 4.8p1.4%; P 0.03) and decrease in the HF component (9.1p2.1 % compared with 7.6p1.1 ; P 0.05) than did insulin-resistant patients. Hence healthy subjects showed a greater insulin-related percentage change in the LF\HF ratio (17.8p3.3 %) than did insulin-resistant patients (5.5p1.3%; P 0.01). This latter difference was still significant after adjustment for body fat and MABP (P 0.05).
Results in the whole group of subjects studied
For the pooled data (n l 72), the fasting plasma insulin concentration was correlated with baseline total spectral power (r l k0.37 ; P 0.001) and the LF\HF ratio (r l k0.35 ; P 0.003). Such correlations were still significant (P 0.01 for both) after adjustment for body fat and MABP. In a multivariate linear stepwise analysis (n l 72), the contributions of demographic, anthropometric, cardiovascular and metabolic parameters to the percentage changes in the LF\HF ratio were studied. A model including age, sex, body fat, and waist\hip ratio explained 43 % of the variability in the percentage changes in the LF\HF ratio. In this model, only age (t l k3.82 ; P 0.005) and body fat (t l k3.01 ; P 0.01) were significantly and independently associated with changes in the LF\HF ratio. A further model encompassing age, MABP and changes in heart rate, LBF and plasma noradrenaline concentration was also investigated. This model explained 51 % of the variability in the percentage change in the LF\HF ratio, with age (t l k3.56 ; P 0.007) and MABP (t l k2.88 ; P 0.02) being independently and significantly associated with changes in the LF\HF ratio. The independent roles of body fat, waist\hip ratio, fasting plasma glucose and insulinmediated glucose uptake were also studied. Such a model explained 47 % of the variability in the percentage change in the LF\HF ratio, with body fat (t l k3.11 ; P 0.01) and insulin-mediated glucose uptake (t l 3.48 ; P 0.008) significantly and independently associated with changes in the LF\HF ratio.
Control study
In the control study (infusion of saline), plasma glucose and insulin concentrations were slightly but not significantly decreased. Furthermore, no significant changes in hormonal, cardiovascular or HRV parameters were observed. 
DISCUSSION
Our study demonstrates that : (a) the baseline LF component and LF\HF ratio are lower in healthy subjects than in patients with chronic hyperinsulinaemia (insulin resistance) ; (b) insulin infusion stimulates cardiac ANS activity in healthy subjects, but not in insulin-resistant patients ; and (c) insulin exerts different effects on cardiac ANS activity in healthy subjects and insulin-resistant patients ; such differences seem to be related to the degree of insulin resistance, but are independent of the causes of insulin resistance. It has been reported that glucose ingestion stimulates cardiac ANS activity in subjects with different proportions of body fat [3] , and that an inverse relationship exists between body fat content and glucose-induced stimulation of cardiac ANS activity [3] . Whether the stimulatory effect of glucose was mediated by the concurrent rise in the plasma insulin concentration was an unresolved question. Nevertheless, insulin action rather than plasma glucose seems to be responsible for the stimulatory effects of the sympathetic nervous system during glucose loading [5, 15, 16] . Thus a euglycaemic hyperinsulinaemic glucose clamp would seem to be an appropriate technique for assessing the potential role of insulin in cardiac ANS activity. This hypothesis is also supported by the fact that an acute rise in the plasma insulin concentration shifts the cardiac ANS balance in a dose-dependent manner towards a sympathetic activation in healthy subjects [6, 7] . Nevertheless, possible differences between the effects of an acute rise in the plasma insulin concentration and continuous chronic hyperinsulinaemia on cardiac ANS activity have not yet been addressed. Interestingly, in obese insulin-resistant patients, insulin-related stimulation of cardiac ANS activity was only evident at pharmacological plasma insulin concentrations, but was absent at plasma insulin concentrations found under post-prandial conditions [7] .
Whether the lack of an effect of insulin on cardiac ANS activity is specific for obese patients or is a more general hallmark of insulin resistance was not known. Our study shows that an acute rise in the plasma insulin concentration fails to stimulate cardiac ANS activity in different groups of patients affected by insulin resistance. The reason why an acute rise in plasma insulin concentration stimulates cardiac ANS activity in healthy subjects, but is ineffective in insulin-resistant patients, is still unknown. Muscelli et al. [6] demonstrated that insulin infusion stimulated the LF\HF ratio and inhibited total spectral power in healthy subjects, a result confirmed in our study. Such data suggest that acute hyperinsulinaemia might attenuate the variability in sinoatrial node activity in response to both sympathetic and parasympathetic influences in healthy subjects [6] . In the present study, insulin-mediated changes in LBF and plasma noradrenaline concentration were similar in all study groups, and were independent of insulin-mediated glucose uptake, a result also reported by others [17] . Thus differences in insulin-mediated changes in HRV parameters between healthy subjects and insulin-resistant patients are unlikely to be due to changes in LBF or plasma noradrenaline concentration.
Thus our data demonstrate an inability of insulin to stimulate cardiac ANS activity in the insulin-resistant state, an effect that is independent of the cause(s) of insulin resistance. Chronic hyperinsulinaemia, such as that found in insulin-resistant patients, might play a role. The evidence that changes in plasma insulin concentration did not affect the basal microneurography score in hyperinsulinaemic\insulin-resistant patients [16, 18, 19] also supports such a hypothesis. Hence one can hypothesize that chronic hyperinsulinaemia may be the signal that causes attenuation of baroreflex responses and prevents enhancement of cardiac sympathetic tone by an acute rise in insulin. Thus, if the LF component is influenced mainly by baroreceptor activity, one may hypothesize that hyperinsulinaemia\insulin resistance has a direct effect on baroreflex mechanisms. Such an effect would explain the blunted response to insulin infusion in insulin-resistant patients [20, 21] .
It is important to note that the pathophysiological interpretation of the LF\HF ratio is not always unequivocal. In fact, the LF component is a result of a response of the sympathetic system and\or the vascular responsiveness to any mechanical change in blood pressure sensed by the baroreceptor. In contrast, the HF component is often interpreted as reflecting efferent parasympathetic activity at the cardiac level, whereas at the vascular level it largely reflects the mechanical effects of respiration on cardiac output. Thus the LF\HF ratio might reflect at a cardiac level a complex interaction of the sympathovagal balance, modulated by the gain of the baroreflex arc and particularly the vagal arm of the baroreflex [20] [21] [22] . Such interactions between the cardiovascular apparatus and ANS activity make the pathophysiolological interpretation of HRV parameters difficult, especially when complex metabolic variables (such as insulin resistance) are considered.
In conclusion, our study demonstrates that insulin fails to stimulate cardiac ANS activity in insulin-resistant patients, independently of the causes of insulin resistance. Nevertheless, further studies are required in order to define the precise relationship between hyperinsulinaemia\insulin resistance and cardiac ANS activity.
